DK3233104T3 - Immunterapi-behandlinger og -sammensætninger - Google Patents

Immunterapi-behandlinger og -sammensætninger Download PDF

Info

Publication number
DK3233104T3
DK3233104T3 DK15871075.6T DK15871075T DK3233104T3 DK 3233104 T3 DK3233104 T3 DK 3233104T3 DK 15871075 T DK15871075 T DK 15871075T DK 3233104 T3 DK3233104 T3 DK 3233104T3
Authority
DK
Denmark
Prior art keywords
immuntery
treatments
compositions
immuntery treatments
Prior art date
Application number
DK15871075.6T
Other languages
Danish (da)
English (en)
Inventor
Laura L Eggink
J Kenneth Hoober
Original Assignee
Susavion Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Susavion Biosciences Inc filed Critical Susavion Biosciences Inc
Application granted granted Critical
Publication of DK3233104T3 publication Critical patent/DK3233104T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK15871075.6T 2014-12-19 2015-12-17 Immunterapi-behandlinger og -sammensætninger DK3233104T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094944P 2014-12-19 2014-12-19
PCT/US2015/066400 WO2016100679A1 (en) 2014-12-19 2015-12-17 Immunotherapy treatments and compositions

Publications (1)

Publication Number Publication Date
DK3233104T3 true DK3233104T3 (da) 2020-03-23

Family

ID=56127600

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15871075.6T DK3233104T3 (da) 2014-12-19 2015-12-17 Immunterapi-behandlinger og -sammensætninger

Country Status (8)

Country Link
US (1) US10624965B2 (enExample)
EP (1) EP3233104B1 (enExample)
JP (1) JP6649953B2 (enExample)
AU (1) AU2015364559B2 (enExample)
CA (1) CA2971471C (enExample)
DK (1) DK3233104T3 (enExample)
ES (1) ES2781673T3 (enExample)
WO (1) WO2016100679A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018039132A1 (en) * 2016-08-24 2018-03-01 Wisconsin Alumni Research Foundation Methods and compositions for the treatment of cancer
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides
CA3185526A1 (en) * 2020-07-28 2022-02-03 Laura L. Eggink Method of treatment of neutrophil-driven inflammatory pathologies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087793A2 (en) * 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
US7838497B2 (en) * 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
EP2262837A4 (en) * 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CA3017298C (en) * 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
GB0920258D0 (en) * 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
WO2013096829A2 (en) 2011-12-22 2013-06-27 Arizona Biomedical Research Commission Activation of cellular assault processes in the treatment of glioblastoma multiforme
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2892558B1 (en) * 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer

Also Published As

Publication number Publication date
EP3233104A4 (en) 2018-06-27
CA2971471C (en) 2023-04-18
JP2018501247A (ja) 2018-01-18
EP3233104A1 (en) 2017-10-25
US20190167789A1 (en) 2019-06-06
AU2015364559B2 (en) 2020-03-26
WO2016100679A1 (en) 2016-06-23
JP6649953B2 (ja) 2020-02-19
WO2016100679A9 (en) 2017-02-23
US10624965B2 (en) 2020-04-21
EP3233104B1 (en) 2020-03-04
CA2971471A1 (en) 2016-06-23
AU2015364559A1 (en) 2017-06-15
ES2781673T3 (es) 2020-09-04

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
IL280863A (en) Autotaxin inhibitors and uses thereof
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
KR20180084891A (ko) 구조 조성물 및 방법
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
DK3130649T3 (da) Haloolefin-baseret sammensætning
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3542812T3 (da) Glycopeptidsammensætninger
LT3102555T (lt) Junginių kompozicijos ir jų panaudojimas
DK3231444T3 (da) Ny behandling
FR3024363B1 (fr) Composition thermogelifiable
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
HUE054204T2 (hu) Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez
PT3261437T (pt) Compostos e composições fungicidas
DK3193840T3 (da) Arimoclomol-formulering
CL2017000639A1 (es) Composición
PT3337506T (pt) Combinações e suas utilizações
EP3236746C0 (en) COMPOSITION
DK3200827T3 (da) Sammensætninger
DK3148513T3 (da) Ceritinib-formulering
DK3233104T3 (da) Immunterapi-behandlinger og -sammensætninger
DK3217964T3 (da) Sammensætning
DK3193856T3 (da) Formulering
FR3019552B1 (fr) Composition filmogene
IL252707A0 (en) Compositions and methods for treating diseases and conditions